Joseph Michael Tuscano, M.D.

Philosophy of Care	Dr. Tuscano believes in high quality, innovative, and compassionate care of his patients. Dr. Tuscano believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests	Dr. Tuscano's areas of specialty include the treatment of leukemia, lymphoma, MDS, and multiple myeloma. He is also a member of the adult stem cell transplant team.
Research/Academic Interests	Dr. Tuscano has both basic/translation and clinical research interests that include the development of novel antibody and other immune-based therapeutics for hematologic malignancies.
Title	Professor
Specialty	Bone Marrow Transplant, Leukemia
Department	Internal Medicine
Division	Hematology and Oncology Malignant Hematology/Cellular Therapy and Transplantation
Center/Program Affiliation	Stem Cell Transplant Program UC Davis Comprehensive Cancer Center Stem Cell Research Program
Address/Phone	UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817 **Phone:** 916-734-5959
Additional Phone	Clinic Fax: 916-703-5261 Clinic Referral Phone: 916-703-5210 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., University of Southern California School of Medicine, Los Angeles CA 1989 B.S., California State University, Sacramento, Sacramento CA 1985
Internships	Internal Medicine, UC Davis Medical Center, Sacramento CA 1989-1992
Residency	Internal Medicine, UC Davis Medical Center, Sacramento CA 1989-1992
Fellowships	Hematology/Oncology, National Institutes of Health, National Cancer Institute, Bethesda MD 1992-1996 Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1997-1998
Board Certifications	American Board of Internal Medicine, Medical Oncology

UCDAVIS HEALTH

Joseph Michael Tuscano, M.D.

Professional Memberships

American Association of Immunologists (AAI)
American Society of Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Hematology
Southwest Oncology Group, Myeloma and Lymphoma Committees

Honors and Awards

Diamond Doctor award (top 1%) by UC Davis Health, 2021
Top Doctor's award by Sacramento Magazine, 2019, 2020
Distinguished Achievement Award by a California State Assembly Resolution, 2018
Certificate of Appreciation: The Leukemia & Lymphoma Society, 2009

Select Recent Publications

For a comprehensive list of Dr. Tuscano's publications, please click here (opens new window).

Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 May 1;107(5):1086-1094. doi:10.3324/haematol.2021.278438. PMID: 34162178.

Poh C, McPherson JD, Tuscano J, Li Q, Parikh-Patel A, Vogel CFA, Cockburn M, Keegan T. Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study. BMC Med. 2022 Apr 26;20(1):165. doi:10.1186/s12916-022-02348-7. PMID:35468782.

Virk HS, Shahlaie K, Ramani B, Perry A, Fragoso R, Tuscano J, Liu YA. Orbital Rosai-Dorfman Disease Presenting as Optic Neuritis. J Neuroophthalmol. 2022 Mar 1;42(1):e293-e296. doi: 10.1097/WNO.0000000000001405. Epub 2021 Nov 19. PMID:35475853.

Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194. 2021.1975190. Epub 2021 Sep 6. PMID:34486920.

UCDAVIS HEALTH

Joseph Michael Tuscano, M.D.

Shimoda M, Lyu Y, Wang KH, Kumar A, Miura H, Meckler JF, Davis RR, Chantarasrivong C, Izumiya C, Tepper CG, Nakajima KI, Tuscano J, Barisone G, Izumiya Y. KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. Commun Biol. 2021 Dec 2;4(1):1330. doi:10.1038/s42003-021-02853-0. PMID: 34857874.

Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. PMID:34781267.

Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi:10.1158/1078-0432. CCR-20-4622. Epub 2021 Jun 4. PMID:34088724.

Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):345-354. e4. doi:10.1016/j.clml.2020.12.021. Epub 2020 Dec 27. PMID:33563582.

Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 Mar;

UCDAVIS HEALTH

Joseph Michael Tuscano, M.D.

21(3):139-146. doi:10.1016/j.clml.2020.12.020. Epub 2020 Dec 24. PMID:33478921.

© 2024 UC Regents

UCDAVIS HEALTH